Novel arenaviral immunotherapy is directed against the prostate cancer targets PAP and PSA; Phase 1/2 trial to commence by early...
Addition of Immunotherapeutic Agent Under Investigation for the Treatment of Ovarian Cancer to Asset PortfolioTAMPA, Fla., July 22, 2022 (GLOBE...
HTL0039732 is a novel EP4 antagonist with potential to treat a wide range of cancers in combination with other immunotherapiesTOKYO,...
€4 million ($4.2 million) research and innovation award for consortium to develop first-in-class smart bioprocessing manufacturing platformLONDON, July 21, 2022...
Research will leverage Artizan’s proprietary IgA-SEQ™ discovery platform to identify gut microbiota that may affect the safety and efficacy of...
European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural...
--6th Orphan Drug Designation granted to toripalimab in the US and EU SHANGHAI, China, July 21, 2022 (GLOBE NEWSWIRE) --...
ITM to supply its medical radioisotope, no-carrier-added Lutetium-177, for the clinical development of Y-mAbs’ Targeted Radionuclide Therapy candidate GD2-SADA: 177Lu-DOTA...
Basel, 21 July 2022 Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Division sales...
Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn.,...
LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation...
Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN),...
NEW YORK, July 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd.(Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company...
Initial Public Offering of 1,215,800 shares of its common stock at KRW 30,000To be listed on the KOSDAQ market on...
PDS0202 neutralized multiple strains of influenza and provided protection against infection in preclinical studiesFLORHAM PARK, N.J., July 14, 2022 (GLOBE...
Ideagen’s PleaseReview will improve review, co-authoring and redaction projects linked to cancer and other oncology treatments US-based pharmaceutical company, Immunomedics, is...
Xenikos is currently preparing to initiate a U.S. pivotal Phase 3 trial.Receiving Fast Track designation from the FDA will facilitate...